Medical Marijuana Might Reduce Nerve Pain Among People Living With HIV/AIDS, Study Says – MedicalNewsToday

“Medical marijuana might reduce the pain of peripheral neuropathy, a type of nerve damage, among people living with HIV/AIDS, according to a study published in the Feb. 13 issue of the journal Neurology, the Washington Post reports (Weiss, Washington Post, 2/13). Donald Abrams of the University of California-San Francisco and colleagues examined the effects of smoking medicinal marijuana among people living with HIV/AIDS during a two-year period beginning in May 2003, the San Francisco Chronicle reports.

The results are “evidence, using the gold standard for clinical research, that cannabis has some medical benefits for a condition that can be severely debilitating,” Abrams said.”

More:  http://www.medicalnewstoday.com/releases/62955.php

Synthetic Agents Related To Active Ingredient In Marijuana Weaken HIV Infection – MedicalNewsToday

“HIV, the virus that causes AIDS, is notorious for hiding within certain types of cells, where it reproduces at a slowed rate and eventually gives rise to chronic inflammation, despite drug therapy. But researchers at Temple University School of Medicine’s Department of Pathology and Laboratory Medicine and Center for Substance Abuse Research (CSAR) recently discovered that synthetic anti-inflammatory substances distantly related to the active ingredient of marijuana may be able to take the punch out of HIV while inside one of its major hideouts – immune cells known as macrophages.

The breakthrough comes at a crucial time in the HIV/AIDS pandemic…

To better understand the connection between inflammation and neurocognitive conditions linked to long-term exposure to HIV, Ramirez and colleagues looked specifically at the CB2 receptor, a protein located on the surface of macrophages. CB2 is a binding site for substances called cannabinoids, the primary active compounds of cannabis (marijuana), and it may play a role in blocking inflammation in the CNS. Unlike its counterpart, the CB1 receptor, which is found primarily on neurons in the brain, CB2 does not mediate the psychoactive effects for which cannabis is popularly known.

Ramirez explained that there has been much pharmacological interest in developing agents that selectively target CB2. Ideally, these compounds would help limit chronic inflammatory responses and would not bind to CB1.

The most promising compounds are those derived from THC (tetrahydrocannabinol), the main active substance in cannabis.”

More: http://www.medicalnewstoday.com/releases/259980.php

Synthetic derivatives of THC may weaken HIV-1 infection to enhance antiviral therapies – MedicalXpress

“A new use for compounds related in composition to the active ingredient in marijuana may be on the horizon: a new research report published in the Journal of Leukocyte Biology shows that compounds that stimulate the cannabinoid type 2 (CB2) receptor in white blood cells, specifically macrophages, appear to weaken HIV-1 infection. The CB2 receptor is the molecular link through which the pharmaceutical properties of cannabis are manifested. Diminishing HIV-1 infection in this manner might make current anti-viral therapies more effective and provide some protection against certain HIV-1 complications.

“The synthetic compounds we used in our study may show promise in helping the body fight HIV-1 infection,'” said Yuri Persidsky, M.D., Ph.D., a researcher involved in the work from the Department of Pathology and Laboratory Medicine at Temple University School of Medicine in Philadelphia, PA. “As compounds like these are improved further and made widely available, we will continue to explore their potential to fight other viral diseases that are notoriously difficult to treat.”

To make this discovery, scientists used a cell culture model to infect human macrophages with HIV-1 and added synthetic compounds similar to the active ingredient in marijuana to activate the CB2 receptor. At different times during the infection, samples from the culture were taken to see if the replication of the HIV virus was decreased. The researchers observed diminished HIV growth and a possible protective effect from some HIV-1 complications.

“HIV/AIDS has posed one of the most significant health challenges in modern medicine,” said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology. “Recent high profile vaccine failures mean that all options need to be on the table to prevent or treat this devastating infection. Research on the role of cannabinoid type 2 receptors and viral infection may one day allow targeting these receptors to be part of combination therapies that use exploit multiple weaknesses of the virus simultaneously.””

http://medicalxpress.com/news/2013-04-synthetic-derivatives-thc-weaken-hiv-.html

Outlawing drugs like marijuana censors science, researchers say – FOX

“The outlawing of drugs such as cannabis, magic mushrooms and other psychoactive substances amounts to scientific censorship and is hampering research into potentially important medicinal uses, leading scientists argued on Wednesday.”

New-Pot.jpg
 

“Laws and international conventions dating back to the 1960s have set back research in key areas such as consciousness by decades, they argued in the journal Nature Reviews Neuroscience.

“The decision to outlaw these drugs was based on their perceived dangers, but in many cases the harms have been overstated,” said David Nutt, a professor of neuropsychopharmacology at Imperial College London.

In a statement accompanying the Nature Reviews paper, he said the laws amounted “to the worst case of scientific censorship since the Catholic Church banned the works of Copernicus and Galileo”.

“The laws have never been updated despite scientific advances and growing evidence that many of these drugs are relatively safe. And there appears to be no way for the international community to make such changes,” he said.

“This hindering of research and therapy is motivated by politics, not science.”

Nutt and Leslie King, both former British government drugs advisers, and co-author David Nichols of the University of North Carolina, called for the use of psychoactive drugs in research to be exempted from severe restrictions.

“If we adopted a more rational approach to drug regulation, it would empower researchers to make advances in the study of consciousness and brain mechanisms of psychosis, and could lead to major treatment innovations in areas such as depression and PTSD,” Nutt said.

Nutt was sacked as a government adviser in 2009 after publicly criticizing the government for ignoring scientific advice on cannabis and ecstasy. He has conducted a small human trial using psilocybin, the psychedelic ingredient in magic mushrooms.

His study, using volunteers, suggested the drug had the potential to alleviate severe forms of depression in people who did not respond to other treatments.

But in April, Nutt said his plans to conduct the first full clinical trial to explore psilocybin as a treatment had stalled because of stringent rules on the use of illegal drugs in research.

The scientists said their call for reform had been endorsed by the British Neuroscience Association and the British Association for Psychopharmacology.”

http://www.foxnews.com/health/2013/06/12/outlawing-drugs-like-marijuana-censors-science-researchers-say/

‘The worst case of scientific censorship since the Catholic Church banned the works of Galileo’: Scientists call for drugs to be legalised to allow proper study of their properties

 “The outlawing of drugs such as cannabis, MDMA and LSD amounts to the “the worst case of scientific censorship since the Catholic Church banned the works of Copernicus and Galileo”, the former Government drugs advisor Professor David Nutt has claimed.”

Professor Nutt, who was dismissed from the Home Office’s advisory council on drugs in 2009 after clashing with ministers, said that UN conventions on drugs in the 1960s and 1970s have delayed the development of “innovative treatments” for PTSD and depression by 30 years and also set back research into areas of neuroscience such as consciousness.

In a paper published today with two other scientists in the journal Nature Reviews Neuroscience, he said that drugs policy is being driven by “politics, not science”.

Professor Nutt left the Home Officer in 2009 after suggesting that taking MDMA ecstasy was no more dangerous than horse-riding and that alcohol and tobacco were more dangerous than many illegal drugs.

The possession of psychoactive drugs such cannabis, MDMA (ecstasy) and LSD for scientific purposes is stringently regulated in the UK and most other countries, in accordance with UN conventions that were agreed in response to the emergence of drug culture in the 1960s and 1970s.

Applying for a Government licence can be costly and time-consuming and many scientists are put off by a culture of “repression” surrounding drug science, Professor Nutt said.

“The laws scare off funders and most scientists are scared because they think if they break the law, they might get arrested,” he told The Independent. “I’m sure at some point someone’s going to arrest me. There is a sense of repression to the point that most people won’t do it.”

The paper, which is published to coincide with a conference on scientific research with psychedelics at Imperial College London, points to evidence that cannabis, MDMA and psychedelics such as LSD and psilocybin (the compound found in magic mushrooms) have unexplored medicinal benefits and argues that laws should be updated.

Small clinical studies of MDMA, which was originally used in the USA in the 1970s to improve communication in psychotherapy sessions, suggested that it could play a highly beneficial role in the treatment of PTSD patients. The paper’s authors said the drug could also help with “end of life anxiety” and couples therapy”.

Medical use of marijuana is already legal in 17 US states, and the drug has been shown to have benefits such as anxiety reduction and pain relief. However, Professor Nutt said that UK restrictions had blocked development of therapeutic applications for any of cannabis’ 16 active ingredients.

LSD, meanwhile, was widely researched in the 1950s and 1960s, with more than 1,000 papers investigating outcomes for more than 40,000 patients, with evidence suggesting that the drug might be an effective treatment for alcoholism, before bans on the drug around the world ended further research.”

-Charlie Cooper

http://www.independent.co.uk/news/science/the-worst-case-of-scientific-censorship-since-the-catholic-church-banned-the-works-of-galileo-scientists-call-for-drugs-to-be-legalised-to-allow-proper-study-of-their-properties-8654514.html

Medical breakthroughs missed because of pointless drug bans

Vx3mkwtp-1370889557 

“In 1632 the Catholic Church convened a case against Galileo on the grounds that his work using the telescope to explore the nature of the heavens contradicted the church’s teaching – the culmination of a long fight that had lasted 16 years.

Galileo was put under house arrest and his research stopped. Some of his inquisitors refused even to look down a telescope, believing it to be the work of the devil. With his life under threat, Galileo retracted his claims that the earth moved around the sun and was not the centre of the universe. A ban by the papal Congregation of the Index on all books advocating the Copernican system of planetary motion – which we use today – was not revoked until 1758.

Three centuries later we have an equivalent case of scientific censorship. In the 1960s and the 1970s the UN effectively banned a whole range of drugs from cannabis, opioids and cocaine through to psychedelics – LSD and “magic mushrooms”. They did this in a futile attempt to reduce the use and harms of these drugs, but both consumption and harms have increased ten-fold since then, and many of the negative effects of these laws include the rise of AIDS and the collapse of law and order in Mexico.

However, another major impact of these laws – restriction of research – has hardly been discussed. Yet this is arguably as significant a problem and must change.

A research black hole

Two of the most limiting areas have been in the fields of research into cannabis and psychedelics, both of which were put into the UN’s most restrictive lists, deemed to have no value to medicine.

Currently in the UK to work with these compounds you need a special licence, which along with additional police checks, costs more than £5000 and takes a year to get. In the UK only three hospitals have these, making clinical research almost impossible. Contrast this with the situation for heroin, a much more abused and harmful drug, which can be held by any hospital with a license.

The field of research that has been most censored is that of psychedelics (LSD and psilocybin) and empathogens (MDMA and Ecstasy).

Before the LSD ban there were more than 1000 publications on its therapeutic potential – its hallucinogenic properties undiscovered until five years after its discovery in 1938. Since then there have been none – despite its proven utility in disorders including alcoholism, end of life suffering and cancer pain.

The ban was largely driven by political concerns. Despite being justified by claims of harm such as people dying while trying to fly, its use was also discouraging young people in the US fighting in the Vietnam war.

The psychedelic state is also one of the most intriguing kinds of brain function that can illuminate the fundamental mechanisms of the brain and give us novel insights into consciousness.

Drugs such as MDMA can help conditions such as post traumatic stress disorder.

The banning of cannabis was purely political. It was already being used as a medicine in many countries before it was banned. With the notable exception of The Netherlands, most countries agreed to this dishonest change in status. In the UK, it has criminalised many patients with incurable conditions such as multiple sclerosis who could benefit from the drug.

But it has also led to a severe impairment of medical research into the cannabis plant. There are more than 50 active chemicals in the cannabis plant and many of these were discovered in the UK. However, turning any of these into medicines is very slow due to unnecessarily tough regulations. This has set back UK leadership in the field and wasted huge economic opportunities.

Basic neuroscience research has also been held back. Cannabis works on cannabinoid receptors in the brain – and we have a lot of these – surprisingly more than our dopamine (pleasure and reward) and serotonin receptors (wellbeing and happiness) combined. Cannabinoid receptors do many things and are involved in learning and memory, eating and sleep anxiety.

Their role is therefore of great interest but studying them requires working with compounds such as THC (the element of cannabis that makes people stoned). But again, the regulations make getting these expensive and difficult.

Time to challenge outdated controls

What can be done? It’s very easy once we accept that no meaningful benefits come from controls that have been left unchallenged for 50 years. In the UK we can exempt hospitals from the need to have the licences – they could hold cannabis safely alongside heroin. We can also exempt very small amounts of the drugs (below a clinically meaningful dose for example) from any control at all, so that scientists doing basic research can work without hindrance.

The transfer of small amounts of test compounds between different countries should also be exempt from import and export rules that now apply to every compound on a case-by-case basis – which also significantly impairs detection of new “legal highs” because samples can’t easily be shared across Europe.

Ideally, a fundamental change in the world perspective should also happen. The UN conventions are outmoded and should be fully revised. This can happen at the 2016 UN General Assembly Special Session (UNGASS) meeting into drug control – the first opportunity to do so in some time.

In the meantime, let’s get scientists as well as patient and civil liberty groups working together to achieve this. We need more petitions. We need more leadership. Some countries are already showing this. New Zealand is beginning to change where it stands on legal highs with the Psychoactive Substances Bill. Some South American countries are also now taking a more rational approach. What we need to do now is put science at the forefront of research.”

-David Nutt

http://theconversation.com/medical-breakthroughs-missed-because-of-pointless-drug-bans-15072

Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents.

“Marijuana has been reported to be an effective antinauseant and antiemetic in patients receiving cancer chemotherapy.

Whether this is due to psychological changes, central antiemetic properties and/or direct effects on gastrointestinal (GI) function is not known. The purpose of these investigations was to determine whether the major constituents of marijuana and the synthetic cannabinoid nabilone have any effects on GI function which can be detected in rodent models of GI transit and motility. Intravenous delta 9-tetrahydrocannabinol (delta 9-THC) slowed the rate of gastric emptying and small intestinal transit in mice and in rats. Delta 9,11-THC, cannabinol and nabilone given i.v. also inhibited small intestinal transit in mice, but were less effective in reducing gastric emptying. Cannabidiol given i.v. had no effect on gastric emptying or intestinal transit. Those cannabinoids which inhibited GI transit did so at doses equal to, or lower, than those reported to produce central nervous system activity. In rats, delta 9-THC produced greater inhibition of gastric emptying and small intestinal transit than large bowel transit, indicating a selectivity for the more proximal sections of the gut. In addition, i.v. delta 9-THC decreased the frequency of both gastric and intestinal contractions without altering intraluminal pressure. Such changes probably reflect a decrease in propulsive activity, without change in basal tone.

These data indicate that delta 9-THC, delta 9,11-THC, cannabinol and nabilone (but not cannabidiol) exert an inhibitory effect on GI transit and motility in rats.”

http://www.ncbi.nlm.nih.gov/pubmed/2542532

Pharmacological synergism between cannabinoids and paclitaxel in gastric cancer cell lines.

“Orally applicable Delta9-tetrahydrocannabinol and its synthetic derivatives have been used as antiemetic drugs during chemotherapy in cancer patients.

 However, it is not well known how cannabinoids influence the effects of chemotherapeutic agents on malignant tumors. In this study, we investigated how the endogenous cannabinoid anandamide (AEA) changes the effect of paclitaxel on gastric cancer cell lines.

 In the human gastric cancer cell line, HGC-27, which express cannabinoid receptor 1 (CB1), AEA stimulated proliferation at concentrations under 1 microM, while it strongly suppressed proliferation through the induction of apoptosis at 10 microM. This bimodal effect was reproduced by a selective CB1 agonist, arachidonyl-2-chloroethylamide, although the effects were less marked. When AEA was used with paclitaxel, AEA at 10 microM synergistically enhanced the cytotoxic effect of paclitaxel, whereas it showed no significant effect at lower concentrations. Flow cytometric analysis revealed that addition of 10 microM AEA synergistically enhanced paclitaxel-induced apoptosis, possibly through the activation of caspase-3, -8, and -9.

Our results suggest that cannabinoids could be a good palliative agent for cancer patients receiving paclitaxel.”

http://www.ncbi.nlm.nih.gov/pubmed/19394652

Effect of a synthetic cannabinoid agonist on the proliferation and invasion of gastric cancer cells.

“Although cannabinoids are associated with antineoplastic activity in a number of cancer cell types, the effect in gastric cancer cells has not been clarified. In the present study, we investigated the effects of a cannabinoid agonist on gastric cancer cell proliferation and invasion.

The cannabinoid agonist WIN 55,212-2 inhibited the proliferation of human gastric cancer cells in a dose-dependent manner and that this effect was mediated partially by the CB(1) receptor. We also found that WIN 55,212-2 induced apoptosis and down-regulation of the phospho-AKT expression in human gastric cancer cells. Furthermore, WIN 55,212-2 treatment inhibited the invasion of gastric cancer cells, and down-regulated the expression of MMP-2 and VEGF-A through the cannabinoid receptors.

Our results open the possibilities in using cannabinoids as a new gastric cancer therapy.”

http://www.ncbi.nlm.nih.gov/pubmed/20336665

Antiproliferative mechanism of a cannabinoid agonist by cell cycle arrest in human gastric cancer cells.

“For gastric cancers, the antineoplastic activity of cannabinoids has been investigated in only a few reports and knowledge regarding the mechanisms involved is limited. We have reported previously that treatment of gastric cancer cells with a cannabinoid agonist significantly decreased cell proliferation and induced apoptosis.

Here, we evaluated the effects of cannabinoids on various cellular mediators involved in cell cycle arrest in gastric cancer cells. AGS and MKN-1 cell lines were used as human gastric cancer cells and WIN 55,212-2 as a cannabinoid agonist.

 …Cell cycle arrest preceded apoptotic response. Thus, this cannabinoid agonist can reduce gastric cancer cell proliferation via G1 phase cell cycle arrest, which is mediated via activation of the MAPK pathway and inhibition of pAKT.”

http://www.ncbi.nlm.nih.gov/pubmed/21312237